Schering Corporation

Schering-plough Corporation

Schering Coporation

Wing C Tom

Robert G Aslanian

Kevin D McCormick

Neng-Yang Shih

Michael Berlin

Pauline C Ting

Daniel M Solomon

Mwangi W Mutahi

Joseph A Kozlowski

Wayne D Vaccaro

Margaret H Sherlock

Sundeep Dugar

Samuel Chackalamannil

Michael J Green

John W Clader

Stuart B Rosenblum

Stuart W McCombie

Joel G Berger

Christopher W Boyce

Wei K Chang

Pietro Mangiaracina

Theodros Asberom

Susan F Vice

Allen Barnett

Derek B Lowe

Robert D McQuade

Lian-Yong Chen

Margaret E Browne

John J Piwinski

Jayaram R Tagat

Wang Yuguang

Manuel De Lera Ruiz

Junying Zheng

Xiaohong Zhu

David J Blythin

Craig D Boyle

Ho-Jane Shue

Jianhua Chao

Xiao Chen

Qingbei Zeng

Yuguang Wang

Henry A Vaccaro

James J Kaminski

Jianhua Cao

Ying Huang

Richard J Friary

Steven K White

Nicholas I Carruthers

Vera A Seidl

Joe F Lee

Shing-Chun C Wong

Margaret H Scherlock

Javaram R Tagat

Michael Y Berlin

Kevin D Mc Cormick

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein Mis N; X is a bond, optionally substituted alkylene, alkenylene, &#x2014;O&#x2014;, &#x2014;CHN(R)&#x2014;, &#x2014;N(R)CH&#x2014;, &#x2014;N(R)&#x2014;, &#x2014;NHC(O)&#x2014;, &#x2014;OCH&#x2014;, &#x2014;CHO&#x2014;, or &#x2014;S(O)&#x2014;; and Y is &#x2014;(CH)&#x2014;, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;C(&#x2550;NOR)&#x2014; or &#x2014;SO&#x2014;;

Substituted aniline derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

[object Object]

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: and X is &#x2014;O&#x2014; or &#x2014;S&#x2014;; and X is &#x2014;O&#x2014;, &#x2014;S&#x2014; or &#x2014;NR&#x2014;; 

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Non-imidazole compounds

Disclosed are novel compounds of the formula wherein Ris benzimidazolone derivative, Mand Mare optionally substituted carbon or nitrogen, Rincludes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Disclosed are novel compounds of the formula wherein Ris optionally substituted benzimidazolyl or a derivative thereof; Ris optionally substituted aryl or heteroaryl; Mand Mare C(R) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Benzimidazole derivatives useful as histamine H3 antagonists

Muscarinic antagonists

Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates)

Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.

Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.

The invention relates to compounds of the formula ##STR1## These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.

Piperazino derivatives as neurokinin antagonists

Growing community of inventors

Cedar Grove, NJ, United States of America

Wing C Tom